CBD is important, but don’t forget about the other cannabis compounds that could generate billions of dollars in revenue…

I knew it was going to be the “Year of CBD” in 2019, but even I have been a little surprised to see how fast CBD products are hitting the shelves.

Walk into a Sheetz gas station in Pennsylvania or a Walgreens in Maryland, and you’re going to see CBD oil and capsules.

It makes sense.

Researchers are still studying all the powers of cannabis-based medicine, but CBD has shown that it can relieve pain, reduce anxiety and depression, reduce symptoms related to cancer, reduce acne, lower high blood pressure, and help with substance abuse treatment.

The word is spreading about all of the potential benefits, and that’s why someone who has never used CBD before is willing to pay $39.99 at CVS to buy hemp balm on a whim.

However, as we’ve talked about before, there’s even more opportunities in other health-boosting cannabis compounds that you may not have heard of before.

In fact, cannabis compounds are so promising that Cronos Group was willing to pay a private company $122 million to have them produced…

Why Cronos Group Is Betting on THCV

In 2018, Cronos Group Inc. (Nasdaq: CRON) made a $122 million deal with Ginkgo Bioworks, a Boston-based bioengineering company. Ginkgo is currently a private company.

Through the partnership, the bioengineering firm will create rare cannabinoids in large quantities.

One of those compounds is tetrahydrocannabivarin, or THCV for short. It appears in small quantities in a marijuana plant, so it’s difficult to produce THCV at scale.

But if Gingko can make it in large quantities, it could be a game changer, especially for those shareholders who backed Gingko early. You might not be able to take part in the big gains Gingko brings to its early shareholders, but we can show you how to invest in private companies before they potentially make billions of dollars.

But if you’re looking at this deal a little closer, why would Cronos be willing to pay all that money to produce a lesser-known cannabis compound?

Early research has suggested that THCV could help individuals with diabetes.

Diabetes can produce a number of health issues, which include:

  • Increased thirst
  • Frequent urination
  • Increased hunger
  • Fatigue
  • Blurred vision
  • Slow-healing sores
  • Frequent infections
Cannabis Lots can deliver up to 10X the return in 1/10th of the time of traditional stocks. If you’re ready to take your shot at quick cash, go here now.

On top of all that, it can lead to heart disease, nerve damage, kidney damage, eye damage, and sleep apnea. It can even increase the risk of Alzheimer’s disease.

The estimated economic cost of diagnosed diabetes in 2017 was a staggering $327 billion, and as you can see in the chart published by the Centers for Disease Control and Prevention, the amount of people diagnosed with diabetes in the U.S. since 1958 has skyrocketed.

But there is good news.

A study published in 2013 looked into using THCV as a treatment for diabetes.

The study is titled “The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity.”

It’s complicated, so I’ll skip the medical jargon and get you right to the results. Based on the data, it could be suggested that “THCV may be useful for the treatment of the metabolic syndrome and/or Type 2 diabetes, either alone or in combination with existing treatments.”

Essentially, THCV could be used as a medicine or paired with other medicines to help treat Type 2 diabetes.

Big pharma won’t be happy about that, but it could help improve the lives of millions of people.

Again, we are still in the early stages of understanding the true power of the cannabis plant, but this is all very promising. Although Cronos is working with Gingko Bioworks, I’m not going to add Cronos to our model portfolio just because of the partnership.

However, if there are promising profit opportunities with THCV, I’m going to make sure our members are the first to know.

Greg Miller

Executive Director, National Institute for Cannabis Investors

P.S. THCV isn’t the only thing Big Pharma needs to worry about. Sales in the hemp CBD market are on track to hit $22 billion in the next three years – and with so many medical applications for CBD products, you can bet a good chunk of those sales will be going from Big Pharma’s pockets to CBD companies. In fact, hemp CBD has been shown to help with chronic pain, epilepsy, anxiety, post-traumatic stress disorder, and more… all without the harmful side effects of prescription medication. It’s a win-win for both consumers and the cannabis industry which is why we’ve identified two under-the-radar companies that could skyrocket with this massive industry leap. Find out more information here.


Comments

9 responses to “Companies Will Pay Big Bucks for This Cannabis Compound”

  1. As you know, in the absence of scientific studies, there is considerable controversy about what exactly are the health benefits of CBD. That said, there is widespread and indisputable anecdotal evidence with respect to two conditions for which CBD provides strong benefits (once it’s taken long enough for the receptors to kick in). One is inflammation and the other is chronic pain. Those two benefits should be mentioned in all your articles which discuss this issue.

  2. If the CBD market is exploding, as I hear on these pages then why are the companies for the most part not showing a profit.

  3. Hello,

    (2) Comments:

    1) DOES GREG PUT ANY OF HIS OWN MONEY INTO THE STOCKS HE
    IS LISTING WEEKLY?

    2) RIGHT NOW CGC IS JUST CRAP? IF STZ ADDED A BIT THAT WOULD GIVE INVESTORS CONFIDENCE.

  4. Mike cannabis is in it’s infancy,you don’t need a lot of money to start buying shares of stock.I f you don’t have a trading account yet ,open one with Schwab OR Fidelity.Deposit $100. 00 and ad as much as you can every month.One stock to buy that is relatively cheap is Emerald Health. Everytime you have a few hundred dollars in your account buy one of the companies listed in the portfolio,and keep adding to the better ones. Don’t worry about the ups and downs in this industry now,these are growing pains and as long Mr. Greg Miller is recommending them keep buying more shares of each company . Have patience and within the next two or three years we should all see the fruits of our investing diligence.read all that Mr. Miller writes about and you should not go astray. Don’t let yourself become confused by reading other peoples evaluations of the cannabis industry. I wish you the best and remember patience and persistence are virtues.Good Luck from a fellow investor.

  5. I would like to more of these great stocks and storylines what is going to be the big one that’s coming up next and the government get there head out of the sand look at the tax thy will be getting on everything has to do with cannabis .

  6. Greg if it is known that a company like Canopy Growth is posting terrible numbers and is going to fall in price why is there no recommendation to exit the stock and re-enter when the company finally gets its house in order. Losing 50% or more of the peak share price seems like a bad way to invest. We have been buying stocks but exiting none of them even though most have lost money. Do you plan on ever having us exit and re-enter a stock to maximize profit on that stock? That is what I am looking for from Cannabis Investors. We subscribe for you to give us good advice to make money not ride bad stocks to the bottom.

  7. I second that there are distribution problems, not enough stores open in Canada I read and in some provinces the government is making it difficult, just look at the daclines in the price in the stocks in the portfolio.

Leave a Reply

Your email address will not be published. Required fields are marked *